united therapeutics corp. - UTHR
UTHR
Close Chg Chg %
570.27 -5.46 -0.96%
Closed Market
564.81
-5.46 (0.96%)
Volume: 831.08K
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: united therapeutics corp. - UTHR
UTHR Key Data
| Open $565.00 | Day Range 551.30 - 577.86 |
| 52 Week Range 266.98 - 607.89 | Market Cap $24.75B |
| Shares Outstanding 43.83M | Public Float 42.33M |
| Beta 0.75 | Rev. Per Employee N/A |
| P/E Ratio 20.27 | EPS $30.18 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 708.30K |
UTHR Performance
| 1 Week | 8.03% | ||
| 1 Month | 18.12% | ||
| 3 Months | 13.71% | ||
| 1 Year | 93.12% | ||
| 5 Years | 193.65% |
UTHR Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
16
Full Ratings ➔
About united therapeutics corp. - UTHR
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
UTHR At a Glance
United Therapeutics Corp.
1000 Spring Street
Silver Spring, Maryland 20910
| Phone | 1-301-608-9292 | Revenue | 3.18B | |
| Industry | Biotechnology | Net Income | 1.33B | |
| Sector | Health Technology | 2025 Sales Growth | 10.61% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,400 | |
| View SEC Filings |
UTHR Valuation
| P/E Current | 20.27 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 17.487 |
| Price to Sales Ratio | 7.333 |
| Price to Book Ratio | 2.997 |
| Price to Cash Flow Ratio | 14.95 |
| Enterprise Value to EBITDA | 12.74 |
| Enterprise Value to Sales | 6.416 |
| Total Debt to Enterprise Value | N/A |
UTHR Efficiency
| Revenue/Employee | 2,273,357.143 |
| Income Per Employee | 953,357.143 |
| Receivables Turnover | 9.088 |
| Total Asset Turnover | 0.413 |
UTHR Liquidity
| Current Ratio | 6.605 |
| Quick Ratio | 6.278 |
| Cash Ratio | 5.209 |
UTHR Profitability
| Gross Margin | 87.922 |
| Operating Margin | 47.67 |
| Pretax Margin | 53.851 |
| Net Margin | 41.936 |
| Return on Assets | 17.325 |
| Return on Equity | 19.715 |
| Return on Total Capital | 18.809 |
| Return on Invested Capital | 19.715 |
UTHR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for United Therapeutics Corp. - UTHR
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.94B | 2.33B | 2.88B | 3.18B | |
Sales Growth
| +14.88% | +20.20% | +23.63% | +10.61% | |
Cost of Goods Sold (COGS) incl D&A
| 151.60M | 257.50M | 309.70M | 384.40M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 51.30M | 53.20M | 72.50M | 85.60M | |
Depreciation
| 51.20M | 52.90M | 71.60M | 84.70M | |
Amortization of Intangibles
| 100.00K | 300.00K | 900.00K | 900.00K | |
COGS Growth
| +23.76% | +69.85% | +20.27% | +24.12% | |
Gross Income
| 1.78B | 2.07B | 2.57B | 2.80B | |
Gross Income Growth
| +14.18% | +15.99% | +24.04% | +8.98% | |
Gross Profit Margin
| +92.17% | +88.94% | +89.24% | +87.92% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 793.80M | 881.50M | 1.19B | 1.28B | |
Research & Development
| 322.90M | 408.00M | 481.00M | 550.00M | |
Other SG&A
| 470.90M | 473.50M | 709.70M | 731.10M | |
SGA Growth
| -9.23% | +11.05% | +35.08% | +7.59% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 12.90M | 3.60M | (18.30M) | |
EBIT after Unusual Expense
| 978.00M | 1.18B | 1.38B | 1.54B | |
Non Operating Income/Expense
| 5.00M | 148.70M | 204.90M | 197.90M | |
Non-Operating Interest Income
| 45.20M | 162.70M | 199.10M | 192.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 32.40M | 59.30M | 42.90M | 19.50M | |
Interest Expense Growth
| +74.19% | +83.02% | -27.66% | -54.55% | |
Gross Interest Expense
| 32.40M | 59.30M | 42.90M | 19.50M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 950.60M | 1.27B | 1.54B | 1.71B | |
Pretax Income Growth
| +60.06% | +34.05% | +20.77% | +11.36% | |
Pretax Margin
| +49.09% | +54.75% | +53.49% | +53.85% | |
Income Tax
| 223.30M | 289.50M | 343.90M | 379.20M | |
Income Tax - Current - Domestic
| 274.10M | 353.90M | 408.00M | 280.30M | |
Income Tax - Current - Foreign
| - | - | - | 1.20M | - |
Income Tax - Deferred - Domestic
| (50.80M) | (64.40M) | (64.10M) | 98.20M | |
Income Tax - Deferred - Foreign
| - | - | - | (500.00K) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 727.30M | 984.80M | 1.20B | 1.33B | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 727.30M | 984.80M | 1.20B | 1.33B | |
Net Income Growth
| +52.86% | +35.40% | +21.35% | +11.68% | |
Net Margin Growth
| +37.56% | +42.31% | +41.53% | +41.94% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 727.30M | 984.80M | 1.20B | 1.33B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 727.30M | 984.80M | 1.20B | 1.33B | |
EPS (Basic)
| 15.9846 | 21.0427 | 26.4403 | 30.1287 | |
EPS (Basic) Growth
| +50.84% | +31.64% | +25.65% | +13.95% | |
Basic Shares Outstanding
| 45.50M | 46.80M | 45.20M | 44.30M | |
EPS (Diluted)
| 14.9959 | 19.8149 | 24.6412 | 27.8643 | |
EPS (Diluted) Growth
| +49.08% | +32.14% | +24.36% | +13.08% | |
Diluted Shares Outstanding
| 48.50M | 49.70M | 48.50M | 47.90M | |
EBITDA
| 1.04B | 1.24B | 1.45B | 1.60B | |
EBITDA Growth
| +41.14% | +19.14% | +16.74% | +10.58% | |
EBITDA Margin
| +53.82% | +53.35% | +50.38% | +50.36% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 633.00 | |
| Number of Ratings | 16 | Current Quarters Estimate | 7.213 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 29.437 | |
| Last Quarter’s Earnings | 6.77 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 27.86 | Next Fiscal Year Estimate | 33.437 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 11 | 11 | 13 | 12 |
| Mean Estimate | 7.21 | 7.31 | 29.44 | 33.44 |
| High Estimates | 8.27 | 8.77 | 34.50 | 40.08 |
| Low Estimate | 6.49 | 6.42 | 25.71 | 23.21 |
| Coefficient of Variance | 8.59 | 10.27 | 9.24 | 17.06 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 10 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for United Therapeutics Corp. - UTHR
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for United Therapeutics Corp. - UTHR
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 3, 2026 | Judy D. Olian Director | 4,845 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $509.55 per share | 2,468,769.75 |
| Feb 26, 2026 | Christopher Causey Director | 4,190 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $520 per share | 2,178,800.00 |
| Feb 26, 2026 | Christopher Causey Director | 5,190 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $119.76 per share | 621,554.40 |
| Feb 26, 2026 | Christopher Causey Director | 6,320 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 41,800 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 36,781 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $478.92 per share | 17,615,156.52 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 38,248 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $478.15 per share | 18,288,281.20 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 40,348 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $477.1 per share | 19,250,030.80 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 41,462 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.89 per share | 19,731,351.18 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 42,343 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.09 per share | 20,116,735.87 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 43,402 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $473.23 per share | 20,539,128.46 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 43,690 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $472.76 per share | 20,654,884.40 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 44,465 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $471.36 per share | 20,959,022.40 |
| Feb 20, 2026 | Paul A. Mahon EVP & GENERAL COUNSEL | 45,081 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $146.03 per share | 6,583,178.43 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 82,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 86,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 2,130 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $474.22 per share | 1,010,088.60 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 4,130 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $120.26 per share | 496,673.80 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 130 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.1 per share | 61,763.00 |
| Nov 21, 2025 | Martine A. Rothblatt Chairperson & CEO; Director | 1,630 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $472.6 per share | 770,338.00 |